Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer
Status:
Enrolling by invitation
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether 4 cycles of neoadjuvant CapOx chemotherapy
is more effective than the upfront surgery in patients with intermediate risk CRM"-" mid and
upper rectal cancer.